Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors

J. Voortman, Taishi Harada, R. P. Chang, J. K. Killian, M. Suuriniemi, W. I. Smith, P. S. Meltzer, M. Lucchi, Y. Wang, G. Giaccone

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background. We evaluated the mutation status of c-Met in small cell lung cancer (SCLC) and neuroendocrine tumors (NET), for which relatively limited therapeutic targets have been explored. Materials and Methods. c-Met was re-sequenced using cell lines and clinical samples. For in vitro studies, DNA constructs containing a juxtamembrane domain (JMD) and tyrosine kinase domain (TKD) were generated. Detected mutations were introduced into the construct and effects on c-Met phosphorylation and interaction with tyrosine kinase inhibitor drugs BMS777607 and SU11274 were assessed. Results. 97 specimens were analyzed: 13 SCLC and 2 pulmonary carcinoid cell lines, 46 SCLC and 36 NET clinical specimens. Mutations were only detected in the JMD. No mutations were detected in the TKD. Found mutations consisted of the previously reported R988C and T1010I mutations. One novel JMD mutation, P996S, was detected in a SCLC specimen. The mutation rate in SCLC cell lines was 25% (31% including a derivative cell line), and 6.5% in clinical specimens. The mutation rate in NET was 8.3%. In vitro, there were no differences between wild type, R988C or T1010I mutants regarding c-Met phosphorylation at Y1003, located in the JMD, and at Y1234/1235, located in the TKD. BMS777607 and SU11274 were shown to inhibit phosphorylation of c-Met in wild type and R988C and T1010I mutants in a similar fashion. Conclusions. In SCLC and neuroendocrine tumors MET mutations are relatively rare. Detected mutations were located in the juxtamembrane domain and were of no functional relevance as they did not influence c-Met phosphorylation, regardless of TKI treatment.

Original languageEnglish
Pages (from-to)833-840
Number of pages8
JournalCurrent Pharmaceutical Design
Volume19
Issue number5
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Neuroendocrine Tumors
Small Cell Lung Carcinoma
Mutation
Protein-Tyrosine Kinases
Phosphorylation
Cell Line
Therapeutics
Mutation Rate
Carcinoid Tumor
Lung
DNA

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

Voortman, J., Harada, T., Chang, R. P., Killian, J. K., Suuriniemi, M., Smith, W. I., ... Giaccone, G. (2013). Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. Current Pharmaceutical Design, 19(5), 833-840. https://doi.org/10.2174/138161213804547196

Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. / Voortman, J.; Harada, Taishi; Chang, R. P.; Killian, J. K.; Suuriniemi, M.; Smith, W. I.; Meltzer, P. S.; Lucchi, M.; Wang, Y.; Giaccone, G.

In: Current Pharmaceutical Design, Vol. 19, No. 5, 01.01.2013, p. 833-840.

Research output: Contribution to journalArticle

Voortman, J, Harada, T, Chang, RP, Killian, JK, Suuriniemi, M, Smith, WI, Meltzer, PS, Lucchi, M, Wang, Y & Giaccone, G 2013, 'Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors', Current Pharmaceutical Design, vol. 19, no. 5, pp. 833-840. https://doi.org/10.2174/138161213804547196
Voortman, J. ; Harada, Taishi ; Chang, R. P. ; Killian, J. K. ; Suuriniemi, M. ; Smith, W. I. ; Meltzer, P. S. ; Lucchi, M. ; Wang, Y. ; Giaccone, G. / Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. In: Current Pharmaceutical Design. 2013 ; Vol. 19, No. 5. pp. 833-840.
@article{c387604fee0045a08fe3a7d970327e03,
title = "Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors",
abstract = "Background. We evaluated the mutation status of c-Met in small cell lung cancer (SCLC) and neuroendocrine tumors (NET), for which relatively limited therapeutic targets have been explored. Materials and Methods. c-Met was re-sequenced using cell lines and clinical samples. For in vitro studies, DNA constructs containing a juxtamembrane domain (JMD) and tyrosine kinase domain (TKD) were generated. Detected mutations were introduced into the construct and effects on c-Met phosphorylation and interaction with tyrosine kinase inhibitor drugs BMS777607 and SU11274 were assessed. Results. 97 specimens were analyzed: 13 SCLC and 2 pulmonary carcinoid cell lines, 46 SCLC and 36 NET clinical specimens. Mutations were only detected in the JMD. No mutations were detected in the TKD. Found mutations consisted of the previously reported R988C and T1010I mutations. One novel JMD mutation, P996S, was detected in a SCLC specimen. The mutation rate in SCLC cell lines was 25{\%} (31{\%} including a derivative cell line), and 6.5{\%} in clinical specimens. The mutation rate in NET was 8.3{\%}. In vitro, there were no differences between wild type, R988C or T1010I mutants regarding c-Met phosphorylation at Y1003, located in the JMD, and at Y1234/1235, located in the TKD. BMS777607 and SU11274 were shown to inhibit phosphorylation of c-Met in wild type and R988C and T1010I mutants in a similar fashion. Conclusions. In SCLC and neuroendocrine tumors MET mutations are relatively rare. Detected mutations were located in the juxtamembrane domain and were of no functional relevance as they did not influence c-Met phosphorylation, regardless of TKI treatment.",
author = "J. Voortman and Taishi Harada and Chang, {R. P.} and Killian, {J. K.} and M. Suuriniemi and Smith, {W. I.} and Meltzer, {P. S.} and M. Lucchi and Y. Wang and G. Giaccone",
year = "2013",
month = "1",
day = "1",
doi = "10.2174/138161213804547196",
language = "English",
volume = "19",
pages = "833--840",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors

AU - Voortman, J.

AU - Harada, Taishi

AU - Chang, R. P.

AU - Killian, J. K.

AU - Suuriniemi, M.

AU - Smith, W. I.

AU - Meltzer, P. S.

AU - Lucchi, M.

AU - Wang, Y.

AU - Giaccone, G.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background. We evaluated the mutation status of c-Met in small cell lung cancer (SCLC) and neuroendocrine tumors (NET), for which relatively limited therapeutic targets have been explored. Materials and Methods. c-Met was re-sequenced using cell lines and clinical samples. For in vitro studies, DNA constructs containing a juxtamembrane domain (JMD) and tyrosine kinase domain (TKD) were generated. Detected mutations were introduced into the construct and effects on c-Met phosphorylation and interaction with tyrosine kinase inhibitor drugs BMS777607 and SU11274 were assessed. Results. 97 specimens were analyzed: 13 SCLC and 2 pulmonary carcinoid cell lines, 46 SCLC and 36 NET clinical specimens. Mutations were only detected in the JMD. No mutations were detected in the TKD. Found mutations consisted of the previously reported R988C and T1010I mutations. One novel JMD mutation, P996S, was detected in a SCLC specimen. The mutation rate in SCLC cell lines was 25% (31% including a derivative cell line), and 6.5% in clinical specimens. The mutation rate in NET was 8.3%. In vitro, there were no differences between wild type, R988C or T1010I mutants regarding c-Met phosphorylation at Y1003, located in the JMD, and at Y1234/1235, located in the TKD. BMS777607 and SU11274 were shown to inhibit phosphorylation of c-Met in wild type and R988C and T1010I mutants in a similar fashion. Conclusions. In SCLC and neuroendocrine tumors MET mutations are relatively rare. Detected mutations were located in the juxtamembrane domain and were of no functional relevance as they did not influence c-Met phosphorylation, regardless of TKI treatment.

AB - Background. We evaluated the mutation status of c-Met in small cell lung cancer (SCLC) and neuroendocrine tumors (NET), for which relatively limited therapeutic targets have been explored. Materials and Methods. c-Met was re-sequenced using cell lines and clinical samples. For in vitro studies, DNA constructs containing a juxtamembrane domain (JMD) and tyrosine kinase domain (TKD) were generated. Detected mutations were introduced into the construct and effects on c-Met phosphorylation and interaction with tyrosine kinase inhibitor drugs BMS777607 and SU11274 were assessed. Results. 97 specimens were analyzed: 13 SCLC and 2 pulmonary carcinoid cell lines, 46 SCLC and 36 NET clinical specimens. Mutations were only detected in the JMD. No mutations were detected in the TKD. Found mutations consisted of the previously reported R988C and T1010I mutations. One novel JMD mutation, P996S, was detected in a SCLC specimen. The mutation rate in SCLC cell lines was 25% (31% including a derivative cell line), and 6.5% in clinical specimens. The mutation rate in NET was 8.3%. In vitro, there were no differences between wild type, R988C or T1010I mutants regarding c-Met phosphorylation at Y1003, located in the JMD, and at Y1234/1235, located in the TKD. BMS777607 and SU11274 were shown to inhibit phosphorylation of c-Met in wild type and R988C and T1010I mutants in a similar fashion. Conclusions. In SCLC and neuroendocrine tumors MET mutations are relatively rare. Detected mutations were located in the juxtamembrane domain and were of no functional relevance as they did not influence c-Met phosphorylation, regardless of TKI treatment.

UR - http://www.scopus.com/inward/record.url?scp=84876736163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876736163&partnerID=8YFLogxK

U2 - 10.2174/138161213804547196

DO - 10.2174/138161213804547196

M3 - Article

VL - 19

SP - 833

EP - 840

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 5

ER -